United States-based PDL BioPharma Inc (Nasdaq: PDLI) has named Edward A Imbrogno as its new vice president and chief financial officer, it was reported on Monday.
Imbrogno joined the company as vice president of Finance in October 2018, bringing more than 30 years of public accounting and financial reporting experience. He was appointed as the company's chief accounting officer in June 2019 and assumed the additional responsibilities as acting chief financial officer in November 2019. He will continue to report to president and chief executive officer, Dominique Monnet.
Imbrogno will continue his duties as the company's chief accounting officer and will receive no incremental compensation for his additional services to the company.
ELIAS Animal Health names new chief revenue officer
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development
HealthTrackRx names new chief medical officer
PureTech announces launch of Seaport Therapeutics with USD100m Series A financing
Orsini Specialty Pharmacy names new CFO and EVP of Trade Relations and Account Management
Enable Biosciences names new chief financial officer
Cadenza Bio names new director
Ligand Pharmaceuticals launches Pelthos Therapeutics to drive ZELSUVMI commercialisation